Xencor XmAb23104 (Advanced Solid Tumors)
What is the Purpose of this Study?
If you choose to join this study, you will:
- Have an infusion of the study drug (XmAb23104) on days 1 and 15 of a 28-day cycle
- Potentially have three infusions of the drug ipilimumab (once every three weeks) through the first 2 cycles
- Provide old or new tumor tissue
- Have an eye exam
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have tests of your heart (ECG)
- Have an infusion of the study drug (XmAb23104) on days 1 and 15 of a 28-day cycle
- Potentially have three infusions of the drug ipilimumab (once every three weeks) through the first 2 cycles
- Provide old or new tumor tissue
- Have an eye exam
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have tests of your heart (ECG)
What is the Condition Being Studied?
Advanced solid tumors that have gotten worse after treatment with standard cancer therapies or for which there are no available therapies.
Who Can Participate in this Study?
Adults with advanced solid tumors who:
- Have cancer that has gotten worse after treatment with standard therapies
- Have no remaining treatment options
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to find out if an experimental drug, XmAb23104, is safe and effective against your cancer when given with and without the drug Ipilimumab.
Study Details
Full Title
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Principal Investigator
Christopher Hoimes
Instructor in the Department of Medicine
Protocol Number
IRB:
PRO00102372
NCT:
NCT03752398
ClinicalTrials.gov
View on ClinicalTrials.gov